Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2022 08:00 ET | Source: Agenus Inc.

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer...
August 02, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Participate at BTIG Biotechnology Conference

LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
August 01, 2022 08:30 ET | Source: Agenus Inc.

Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors

Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical data support best-in-class potential of AGEN1571 LEXINGTON,...
July 27, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
June 30, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Participate at William Blair’s Biotech Focus Conference

LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
June 29, 2022 07:00 ET | Source: Agenus Inc.

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapyResponses to botensilimab/balstilimab were durable, with 80%...
June 21, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress

LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
June 10, 2022 08:00 ET | Source: Agenus Inc.

GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions

First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and aboveThird AS01 adjuvanted vaccine containing QS-21 STIMULON to deliver...
May 31, 2022 08:30 ET | Source: Agenus Inc.

Agenus Advances Portfolio with 6 Clinical Collaborations

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to...
May 25, 2022 08:30 ET | Source: Agenus Inc.

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...